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Gene selection is an important task in bioinformatics studies, because the accuracy of cancer classiﬁca-
tion generally depends upon the genes that have biological relevance to the classifying problems. In this
work, randomization test (RT) is used as a gene selection method for dealing with gene expression data.
In the method, a statistic derived from the statistics of the regression coefﬁcients in a series of partial
least squares discriminant analysis (PLSDA) models is used to evaluate the signiﬁcance of the genes.
Informative genes are selected for classifying the four gene expression datasets of prostate cancer, lung
cancer, leukemia and non-small cell lung cancer (NSCLC) and the rationality of the results is validated by
multiple linear regression (MLR) modeling and principal component analysis (PCA). With the selected
genes, satisfactory results can be obtained.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Cancer classiﬁcation based on microarray has become a popular
research topic in bioinformatics, which can be used to detect sub-
types of cancers and produce therapies. A great many of studies
have appeared for cancer classiﬁcation [1–3]. These methods in-
clude principal component analysis (PCA) [4,5], k-nearest neighbor
(k-NN) [6], hierarchical clustering analysis (HCA) [7], support vec-
tor machine (SVM) [8], Bayesian method [9], partial least squares
discriminant analysis (PLSDA) [10], ensemble methods [11], etc.
Among these methods, PLSDA has been the most commonly used
one for cancer classiﬁcation due to its simplicity [12–14]. More-
over, as a dimension reduction technique, PLS has been used in
gene expression data analysis even in the case where the number
of genes exceeds the number of samples.
Except for a few classiﬁcation methods using full genes [15],
classiﬁcation is generally performed based on selecting signiﬁcant
genes for constructing accurate prediction models. Furthermore,
gene selection may provide insights into understanding the under-
lying mechanism of a speciﬁc biological phenomenon. Also, such
information can be useful for designing less expensive experiments
by targeting only a handful of genes [16]. However, how to effec-
tively select signiﬁcant biomarker genes from thousands or even
ten thousands of genes is a difﬁcult problem. A comprehensive re-
view of feature selection methods has been described by Saeys
et al. [17]. Depending on how the genes interact with the construc-
tion of the classiﬁcation model, feature selection techniques can becharacterized into three classes: ﬁlter, wrapper and embedded
methods. Filter methods [18] assess the relevance of features by
looking only at the intrinsic properties of the data, and thus they
are computationally simple and fast. Wrapper methods [19] em-
ploy a selection strategy in the space of all possible feature subsets,
guided by the predictive performance of a classiﬁcation model.
Advantage of these methods includes the interaction between gene
subset search and model selection. However, they may have a
higher risk of over-ﬁtting than ﬁlter methods and may be compu-
tationally intensive. Embedded methods [20] make use of the
internal parameters in a classiﬁcation model to perform feature
selection, and, therefore, the computational cost is reduced but
the advantage of the interaction between the gene selection and
classiﬁcation model is preserved. Based on the three classes of fea-
ture selection techniques, various gene selection algorithms have
been proposed and successfully used in selecting informative
genes for cancer classiﬁcation [21–25]. In our previous works,
Monte Carlo based uninformative variable elimination (MC-UVE)
[26], randomization test (RT) [27], PLS with the inﬂuential vari-
ables (IVs) [28] and latent projective graph (LPG) [29] have been
proposed for selecting informative variables in near-infrared spec-
tral analysis. Among these methods, RT has been proved to be an
efﬁcient approach to extract useful information from the spectra.
The method builds a regular model and a series of random models,
and then evaluates the importance of the variables based on the
signiﬁcance test of coefﬁcients in regular and random models.
The variables with high signiﬁcance can be selected as the informa-
tive ones.
In this study, RT coupled with PLSDA was employed to seek the
signiﬁcant genes for cancer classiﬁcation. A set of PLSDA models
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ated by a statistic. To validate the performance and applicability
of the method, four gene expression datasets were investigated.
The results show that the method can select signiﬁcant genes for
cancer classiﬁcation.2. Methods
2.1. Partial least squares discriminant analysis (PLSDA)
Partial least squares (PLS) regression is a well-knownmethod to
ﬁnd the relationship between predictor variables X and dependent
variables y. In a PLS model, not only the variance of X, but also the
covariance between X and y is taken into account. Therefore, the
central point of PLS is to ﬁnd latent variables in the feature space
that have a maximum covariance with y. PLSDA is a variant of
PLS to improve the separation between classes using a categorical
response variable y. In this study, X is the matrix of gene expres-
sion values and the values of y are given as 1 and 1 for positive
and negative class, respectively. Each row of X matrix represents
the gene expression values of all the genes for each sample, and
each column corresponds to the gene expression values of all sam-
ples for a gene. PLSDA is used for modeling the genes expression
data (X) and the response variable (y) using the training set. In
the calculations, the optimal latent variable (LV) number used in
the modeling is determined by Monte Carlo cross validation
(MCCV). In the prediction, the samples with predicted values above
zero are ascribed to positive class, otherwise to negative class. The
parameters of accuracy (Acc), precision (P), recall (R) and F-mea-
sure (F) are used to evaluate the classiﬁcation effect.2.2. Randomization test (RT)
RT is a method for variable selection by employing the statistics
of the regression coefﬁcients in the models built with permutation
of the dependent variables y in the training set [27]. In the calcu-
lation of RT, a regular model showing the relationship of y and X
is built for reference and a number (M) of random PLSDA models
are built by randomization, i.e., randomly scrambling the indices
of y while keeping the indices of X. In this study, the number of
the permutations is 1000, as discussed in our previous work [27].
In each of the random models, a regression coefﬁcient can be ob-
tained for each gene. Clearly, the regression coefﬁcients of each
gene in the random models must be due to chance. Therefore,
the values of the regression coefﬁcients can be referred to as ‘noise
values’.
A statistic, P, is deﬁned as the fraction of the ‘noise values’
exceeding the regression coefﬁcient in the regular PLSDA model,
Pj ¼ numðjbjj > jb0;jjÞ=M ðj ¼ 1;2; . . . ; pÞ ð1Þ
where j is the index of the genes, and p is the number of genes. bj
and b0,j represent the ‘noise values’ and the regression coefﬁcient
in the regular model of the gene j, and M is the number of random
models. Since the value of the regression coefﬁcient for each gene is
a reﬂection of its importance in the model, the informative or rele-
vant genes generally have coefﬁcients of large absolute values.
Therefore, the ‘noise values’ should be signiﬁcantly smaller than
the coefﬁcients of the normal model, because they are obtained
by randomization, and the signiﬁcance of a gene can be assessed
by its P value. If a cutoff value is deﬁned, the genes whose coefﬁ-
cients are smaller than the threshold should be selected as informa-
tive ones. In this study, all the genes are ranked by their P values,
and thus the genes are selected according to the order from low
to high P values.2.3. RT-PLSDA method
RT-PLSDA means a combination of RT and PLSDA, in which the
coefﬁcients of PLSDA models were used to calculate P values. Four
steps are included in the calculations. Among the steps, the ﬁrst
two steps are used for selecting the informative genes according
to the P values. The third step determines the retained genes by
repetition of RT procedures to make the result more reliable, and
the fourth step involves the modeling and prediction with the se-
lected genes. The calculation details can be described as follows.
(1) With the training set, a regular PLSDA model is built, and the
regression coefﬁcients for the genes are recorded in a 1  p
vector b0. With the same training set, M permutations of y
are performed to buildM PLSDA randommodels. The regres-
sion coefﬁcients are recorded in an M  p matrix b as the
‘noise values’. It should be noted that before the calculation,
auto-scaling were performed to the datasets in order to
eliminate the effect of intensity difference between genes
and make each gene have a comparable contribution to the
classiﬁcation.
(2) P value of each gene is calculated by using Eq. (1), and the
genes are ranked in an ascending order of P values. With a
number (N) of genes with lower P values, the error of
cross-validation (ECV), which is deﬁned as the number of
misclassiﬁed samples, is obtained by MCCV. In the calcula-
tion of MCCV, 50% of the samples in the training set are ran-
domly selected to build the model and predict the remaining
samples, and 1000 repetitions were performed. The ECV
value is calculated by the sum of misclassiﬁed samples num-
ber in the 1000 repetitions. The number of genes with the
minimum ECV value is selected.
(3) Because random permutation is involved in the calculations,
the distribution of P values is not identical in different runs.
A large number of runs may not be necessary considering
the time consumed, 100 was used for ensuring the reliability
and for investigating the repeatability of the method. A fre-
quency number in the 100 runs is used to further describe
the signiﬁcance of each gene. The selected genes are ranked
in a descending order with the frequency number, and with
different number of the selected genes, a series of PLSDA
models are built and the ECV is obtained by MCCV. The opti-
mal number of retained genes can be therefore determined
by the lowest ECV value for the training set as calculated
in step (2).
(4) With the retained genes, a multiple linear regression (MLR)
model for classiﬁcation is built and used to predict the test
set.
In RT method, the distribution of P values is plotted for determi-
nation of the variables with low value. In this study, lgP is used in
place of P to make the distribution more clear. In this case, the
genes with higher values will be more signiﬁcant. It should be
noted that for few genes, P value may be zero when the regression
coefﬁcient in the regular model is larger than all the ‘noise values’.
Such genes are obviously signiﬁcant ones. For these genes, lgP is
deﬁned as 4 because the maximum value of lgP is 3 when only
one of the ‘noise values’ is larger than the regression coefﬁcient
in the regular model.3. Datasets
Four gene expression datasets of prostate cancer [30], lung can-
cer [31], leukemia [32] and non-small cell lung cancer (NSCLC) [33]
were used in this study. A summary of the four datasets are listed
Table 1
Description of the four gene expression datasets.
Dataset # Gene Class Training set Test set Sources
Prostate cancer 12,600 Tumor/normal 68 (35/33) 34 (17/17) KRBDa
Lung cancer 12,533 MPM/ADCA 32 (16/16) 149 (15/134) KRBD
Leukemia 7129 ALL/AML 38 (27/11) 34 (20/14) KRBD
NSCLC 16,380 SCC/AC 39 (14/25) 19 (4/15) NCBIb
a Kent ridge bio-medical dataset, <http://datam.i2r.a-star.edu.sg/datasets/krbd/>.
b NCBI GEO datasets, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10939>.
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the website was used for the lung cancer and Leukemia dataset,
but Kennard–Stone algorithm (KS) [34] was used to divide the
two sets for the prostate cancer and NSCLC datasets. The KS algo-
rithm sequentially selects a subset of samples that are uniformly
distributed over the predictor variables space based on the Euclid-
ean distance between samples.Fig. 2. Variation of ECV values with the number of selected genes.4. Results and discussion
4.1. Gene selection by randomization test
In order to show the procedures of gene selection by RT method,
prostate cancer dataset is used as an example. In the calculations,
eight principal components are used for the dataset. Fig. 1 shows
the lgP values of the 12,600 genes obtained in one independent
run. In the ﬁgure, most of the lgP values are less than one, mean-
ing that their signiﬁcance is near a random variable. Therefore,
these genes are not signiﬁcant at all in the classiﬁcation model.
On the other hand, only a small number of the genes have a large
lgP value, and two of them are 4, corresponding to a zero P value.
The result indicates that there is only a small number of genes are
informative and it may be possible to select the signiﬁcant genes
with the lgP values.
In order to determine the number of signiﬁcant genes, the genes
are ranked in a descending order of lgP values. With a number
(N) of genes with higher lgP values, ECV value is calculated by
MCCV. Fig. 2 shows the variation of ECV with the number of se-
lected genes from N = 9 to 30. The reason for starting with nine
genes is because the number of genes must be bigger than the
LV number of the PLSDA model, and the reason for ending at 30
is just for clarity of the ﬁgure. Calculations show that the variation
after 20 is almost the same until 100. It can be seen that, the ECV
decreases from a large value to a minimum at N = 16, and then the
ECV ﬂuctuates around a number slightly bigger than the minimum.Fig. 1. Distribution of –lgP values.
Fig. 3. Frequency number of the selected genes.The result indicates that the best model for the classiﬁcation can be
obtained with the 16 selected genes.
Because random permutation is involved in the calculations, the
distribution of lgP values may not be identical in different runs.
Therefore, 100 independent runs are performed to obtain a reliable
result. The results show that the number of the selected genes in
the 100 runs is between 10 and 30. Therefore, the frequency num-
ber was calculated for further ranking the selected genes. As de-
ﬁned in the method, the higher the frequency number of a gene,
the more signiﬁcant. Fig. 3 displays the frequency number of the
selected genes. In the ﬁgure, the genes are ordered by the fre-
quency number along the abscissa axis. It is clear that only 48
genes are selected, and most of the genes are selected in a high fre-
quency. With this ﬁgure, the signiﬁcant genes for classiﬁcation can
be selected according to the frequency number. On the other hand,
the result also shows that, although random permutation is
Fig. 4. Variation of ECV values with the number of retained genes.
Fig. 5. Frequency number of the selected genes for the lung cancer (a), leukemia (b)
and NSCLC (c) dataset.
Z. Mao et al. / Journal of Biomedical Informatics 46 (2013) 594–601 597involved, the algorithm has a good reproducibility. Similar result
can be obtained in different independent run.
To determine the number of retained genes, ECV value is calcu-
lated by MCCV with different number of the selected genes from
high to low frequency number. The calculation starts with nine
genes as the same reason mentioned above. The variation of ECV
with the number of retained genes is shown in Fig. 4. It can be seen
that the ECV decreases from a large value to a minimum when the
number of retained genes is 18. Then, with the increase of the
number, the ECV ﬂuctuates slightly, and reaches a minimum at
43. If tested with F criterion [35], however, it can be found that
the ECV values with 18 and 43 genes have no signiﬁcant difference.
Therefore, the 18 genes can be identiﬁed as the signiﬁcant genes
for the classiﬁcation of the dataset.Table 2
Classiﬁcation results for the datasets using RT-PLSDA method.
Dataset Training set
Acc (%) P (%) R (%) F
Prostate cancer 97.06 96.97 96.97 9
Lung cancer 100 100 100 1
Leukemia 97.37 100 87.50 9
NSCLC 94.87 96.00 96.00 9For testing the efﬁciency of the retained signiﬁcant genes in
classiﬁcation of the dataset, the classiﬁcation model with the 18
genes is investigated. Because the number of retained genes is
smaller than that of the samples, MLR model is adopted for model-
ing and prediction to make the model less complicated. An accu-
racy of 97.06% (66/68) was obtained for the training set by leave-
one-out cross validation (LOOCV), and the accuracy for the test
set is 91.18% (31/34). It is obvious that the results are acceptable,
indicating that the genes obtained by the proposed method is
informative enough for the classiﬁcation.
4.2. Applicability of RT-PLSDA method
To further illustrate the performance of the proposed method,
the lung cancer dataset, leukemia dataset and NSCLC dataset are
investigated. In the calculations, 3, 5 and 3 principal components
are used for the three datasets, respectively. Because the same pro-
cedures were used in the calculation and the similar results were
obtained as in the calculation of prostate cancer dataset, only the
frequency number of the genes was given. Fig. 5 shows the fre-
quency numbers of the selected genes for the three datasets. With
the same calculation for the prostate cancer dataset, i.e., the varia-
tion of ECV values with the number of selected genes in MCCV, the
number of signiﬁcant genes for the three datasets is 4, 9 and 7,
respectively.
The rationality of the signiﬁcant genes was also investigated by
MLR models, as did for the prostate cancer dataset. The accuracies,
P, R and F for the training and test sets are summarized in Table 2.
It can be seen that both the accuracies and the statistical parame-
ters are acceptable, demonstrating the rationality of the retained
genes.
4.3. Biological investigation of the selected genes
In order to validate the selected genes, Table 3 summarizes the
index, gene IDentity (Gene ID), deﬁnition and annotation date of
the 18 genes in an order of frequency number.
As labeled in the table, most of these genes are consistent with
the results reported in the previous studies [30,36–40]. For exam-
ples, X07732 was reported to encode hepsin, a serine protease that
overexpresses in most prostate cancers. It has been known as a po-
tential prostate cancer biomarker [41,42]. M84526 encodes an-
other serine protease adipsin that is secreted by adipocytes into
the bloodstream and functions as part of the alternative comple-
ment pathway of the innate immune system [43]. Hokaiwado
et al. [44] showed that glutathione transferase (M96233) mediates
the proliferation of androgen-independent prostate cancer cells.
M22832 has been correlated to different cancer types with consis-
tent up-regulation in tumor [45].
Table 4 lists the information of the four genes for the lung can-
cer datasets. The ﬁrst gene (AL050224) has been selected by Wang
and Simon [46]. It may play a role in the RNA polymerase and the
expression of the gene was found to be high in lung tissues [47].
Wang and Gotoh [37] reported that FBP1 (U21931) was likely to
have high discriminative power for the ADCA and MPM samples.
As for the last two genes in the table, Claudin-7 (AJ011497) wasTest set
(%) Acc (%) P (%) R (%) F (%)
6.97 91.18 100 82.35 90.32
00 97.99 99.25 98.51 98.88
3.33 94.12 100 87.50 93.33
6.00 94.74 100 93.75 96.77
Table 3
Signiﬁcant genes identiﬁed by RT-PLSDA method for classiﬁcation of tumor and normal samples in the prostate cancer dataset.
Index Gene ID Deﬁnition Annotation datea
5890 AJ001625.1 Homo sapiens mRNA for Pex3 protein [36] October 7, 2008
6185 X07732.1 Human hepatoma mRNA for serine protease hepsin [30,36–38] July 15, 2003
6390 AI093155.1 qa97g04.x1 Homo sapiens cDNA, 3 end[36] August 18, 1998
6462 M11433.1 Human cellular retinol-binding protein mRNA, complete cds [30,38] January 8, 1995
9093 W72186.1 Zd69b19.s1 Homo sapiens cDNA, 3 end [39] June 19, 1996
9850 M84526.1 Human adipsin/complement factor D mRNA, complete cds [30,37,38] April 27, 1993
10215 X02152.1 Human mRNA for lactate dehydrogenase-A [40] September 12, 1993
12495 M98539.1 Human prostaglandin D2 synthase gene, exon 7 [30,36] March 31, 1997
4432 AL034399.6 dA191P20.2 (novel Fibronectin type III domain containing protein similar to Ring ﬁnger protein MID1) January 24, 2013
9034 AL050152.1 Homo sapiens mRNA; cDNA DKFZp586K1220 [37] February 18, 2000
11858 U04313.1 Human maspin mRNA, complete cds [38] June 11, 1994
12153 M96233.1 Human glutathione transferase class mu number 4 (GSTM4) gene, complete cds [30,37] December 20, 1994
205 M62895.1 Human lipocortin (LIP) 2 pseudogene mRNA, complete cds-like region January 7, 1995
8981 D13892.1 Human mRNA for carboxyl methyltransferase, complete cds February 14, 2003
9172 AI207842.1 Ao89h09.x1 Homo sapiens cDNA, 3 end [40,41] October 19, 1998
8965 M22382.1 Human mitochondrial matrix protein P1 (nuclear encoded) mRNA, complete cds [32] January 8, 1995
9044 U21128.1 Human lumican mRNA, complete cds March 8, 1996
8843 D14658.1 Human mRNA for KIAA0102 gene, complete cds March 25, 2006
a http://www.ncbi.nlm.nih.gov/nuccore.
Table 4
Signiﬁcant genes selected by RT-PLSDA method for discrimination of ADCA and MPM samples in the lung cancer dataset.
Index Gene ID Deﬁnition Annotation date
4336 AL050224.1 Homo sapiens mRNA; cDNA DKFZp586L2123 [46] February 18, 2000
7249 U21931.1 Human fructose-1,6-biphosphatase (FBP1) gene September 27, 1995
8537 AJ011497.1 Homo sapiens mRNA for Claudin-7 [31] October 7, 2008
7765 X05323.1 Human MOX2 gene for OX-2 membrane glycoprotein, exon 1 and joined CDS [31] November 14, 2006
Table 5
Signiﬁcant genes detected by RT-PLSDA method for classiﬁcation of AML from ALL samples in the leukemia dataset.
Index Gene ID Deﬁnition Annotation date
1829 M22960.1 Protective protein for beta-galactosidase [48] April 27, 1993
1834 M23197.1 CD33 CD33 antigen (differentiation antigen) [32,48,49] November 1, 1994
2020 M55150.1 FAH Fumarylacetoacetate [32,48,49] November 8, 1994
2121 M63138.1 CTSD Cathepsin D (lysosomal aspartyl protease) [48,49] October 31, 1994
3320 U50136.1 Leukotriene C4 synthase (LTC4S) gene [32,48] May 16, 1996
4229 X52056.1 SPI1 Spleen focus forming virus (SFFV) proviral integration oncogene spi1 [49] April 18, 2005
4847 X95735.1 Zyxin [32,48] October 7, 2008
6376 M83652.1 PFC Properdin P factor, complement [32] February 11, 2002
6539 X85116.1 Epb72 gene exon 1 [32,48] November 14, 2006
Table 6
Signiﬁcant genes detected by RT-PLSDA method for classiﬁcation of AC from SCC samples in the leukemia dataset.
Index NCBI reference sequence Deﬁnition Annotation date
15480 NM_003791.2 Membrane-bound transcription factor peptidase, site 1 December 13, 2012
2691 NM_024682.2 TBC1 domain family, member 17 January 7, 2013
11374 NM_022918.3 Transmembrane protein 135 November 12, 2012
11375 NM_018244.4 Ubiquinol-cytochrome c reductase complex chaperone January 12, 2013
13161 NM_002096.2 General transcription factor IIF, polypeptide 1, 74 kDa, mRNA January 27, 2013
15481 NM_020247.4 aarF domain containing kinase 3 (ADCK3), nuclear gene encoding mitochondrial protein, mRNA January 6, 2013
11684 Celera-transcript only assay
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in contrast, MRC OX-2 (X05323) was found overexpressed in
MPM [31]. Therefore, they are considered as biomarkers for the
lung cancer.
Table 5 presents a summary of the nine genes for the leuke-
mia datasets. As labeled in the table, all of the nine genes have
been identiﬁed as signiﬁcant ones in previous studies [32,48,49].
For examples, CD33 (M23197_at) has been developed for tar-geted antibody therapy to kill leukemia AML cells [32,50], and
the zyxin gene (X95735_at) has been shown to encode an LIM
domain protein that is important in cell adhesion of ﬁbroblasts
[51].
Table 6 shows a summary of the seven genes for the NSCLC
dataset. Because the dataset is a relatively new one, it is difﬁcult
to ﬁnd the literatures for biological interpretation of the genes.
Thus further discussions are not given in this paper.
Fig. 6. PCA score plots of the selected genes for the prostate cancer (a), lung cancer (b), leukemia (c) and NSCLC (d) dataset. Open triangles and ﬁlled inverted triangles
represent positive and negative samples, respectively. The numbers in percentage labeled in the axes represent the explained variances of the PCs.
Table 7
Comparison of the results obtained by different methods for the prostate cancer,
leukemia, lung cancer and NSCLC dataset.
Dataset/method # Genes Training set Test set
Prostate cancer dataset
RT-PLSDA 18 97.06% (66/
68)a
91.18% (31/34)
Gaussian processes [36] 13 Unknownb 91.18%c (93/102)
RIRLS [53] 100 Unknown 91.18%c (93/102)
k-TSP [54] 2 Unknown 91.18%c (93/102)
ERGS [21] 10 Unknown 94.12%c (96/102)
WMW [46] 1 Unknown 89.22%c (91/102)
Lung cancer dataset
RT-PLSDA 4 100% (32/32) 97.99% (146/149)
k-TSP [53] 10 Unknown 98.90%c (179/
181)
ERGS [21] 10 Unknown 98.34%c (178/
181)
WMW [46] 1 Unknown 93.37% (169/181)
Gene expression ratios [31] 6 Unknown 99.33% (148/149)
RFE [55] 2 Unknown 98.34% (178/181)
Decision rules [37] 1 93.75% (30/32) 97.32% (145/149)
Leukemia dataset
RT-PLSDA 9 97.37% (37/38) 94.12% (32/34)
RIRLS [53] 50 Unknown 100%c (72/72)
k-TSP [54] 18 Unknown 95.83%c (69/72)
ERGS [21] 10 Unknown 98.61%c (71/72)
Decision rules [37] 2 94.74% (36/38) 100% (34/34)
Neighborhood analysis
[32]
50 94.74% (36/38) 85.29% (29/34)
PLS-LD [12] 50 100% (38/38) 97.06% (33/34)
NSCLC dataset
RT-PLSDA 7 94.87% (37/39) 94.74% (18/19)
a The numbers in parenthesis are the number of correctly classiﬁed samples and
total samples, respectively.
b ‘‘unknown’’ Means that no related data are provided in the literature.
c Results by LOOCV based on all the samples instead of the test sets.
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To further investigate the signiﬁcance of the selected genes, PCA
score plots obtained with the selected genes of the four datasets
are shown in Fig. 6. Using these plots, the distribution of the sam-
ples for the datasets can be observed.
It is clear that a very good clustering occurs for all the four data-
sets, although the result of prostate cancer dataset is relatively not
so satisfactory. By using Fisher linear discriminant [52], the num-
ber of misclassiﬁed samples for the four datasets is 7, 3, 3, and 1,
respectively. The results clearly demonstrate that the retained
genes can describe the nature of the samples in the two classes,
and thus imply that the selected genes are signiﬁcant for discrim-
inating the samples. Therefore, the proposed method may be an
efﬁcient tool for ﬁnding possible biomarkers from gene expression
data.
4.5. Comparison of the classiﬁcation effect with the gene selected by
different methods
In order to investigate the performance of the proposed meth-
od, the number of selected genes by different methods and the
classiﬁcation effect by using these genes are summarized in
Table 7.
At ﬁrst, from the number of selected genes, the difference be-
tween methods can be clearly found. For several methods, the
number is as high as 50 or even 100, but for some methods, the
number is less than 10, even only 1 or 2. However, it is difﬁcult
to do a further comparison of the selected genes for all the method
listed in the table because the genes selected by the compared
methods were not provided. The results may be accounted for by
the small number of the dataset and the properties of the data [56].
As for the classiﬁcation accuracies, the proposed method pro-
duced the results of 97.06% and 91.18% for the training and test
sets, respectively, using the 18 selected genes for the prostate can-
cer dataset. The result is similar to most of the published works,
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based gene selection (ERGS) method produce a slightly different
accuracy. However, it may be noticeable that the accuracy by ERGS
method was obtained by LOOCV of all the samples in the dataset,
instead of the samples in the test set. For the lung cancer dataset,
Gordon et al. [31] obtained the best classiﬁcation among the sum-
marized methods. The proposed method produces a similar result
with the others including by k-top scoring pairs (k-TSP), ERGS,
WMW and recursive feature elimination (RFE), which were ob-
tained by LOOCV. For the leukemia dataset, the accuracy of the pro-
posed method seems not as good as the previously reported ones.
As for the NSCLC dataset, it is still difﬁcult to ﬁnd the reference
data for comparison. The accuracy of 94.87% and 94.74% for the
training and test sets is obtained by the proposed method.
Clearly, the proposed method cannot outperform all the exist-
ing methods. However, it can outperform some of the published
methods, and can obtain a comparable result with most of the pub-
lished methods. The difference in the number of misclassiﬁed sam-
ples is only one or two. More importantly, the results listed in
Table 7 for the proposed method were obtained by an independent
test set, but that for most of the published methods were obtained
by using LOOCV based on all the samples. Generally, the former ob-
tains a more reasonable result. On the other hand, some of the
methods producing high prediction percentage used too large or
small number of the selected genes in the classiﬁcation. For exam-
ples, only one or two genes were used in the classiﬁcation of pros-
tate cancer dataset by k-TSP and WMWmethod and of lung cancer
dataset by WMW, RFE and decision rules method. In some classiﬁ-
cation, however, more than 50 genes were employed. Such results
may be difﬁcult for a biological interpretation.5. Conclusions
Randomization test is employed as a gene selection method.
The method can evaluate the signiﬁcance of a gene by a statistic
of the regression coefﬁcients in a series of random PLSDA models.
Therefore, a few of the signiﬁcant genes can be selected from the
thousands or more genes in an expression data. With repetition
of the calculations, the frequency number of a gene can be further
used as a criterion to evaluate its signiﬁcance. Four datasets of
prostate cancer dataset, lung cancer dataset, leukemia dataset
and NSCLC dataset are investigated by the method. 18, 4, 9 and 7
signiﬁcant genes are identiﬁed, respectively, and the rationality
of the results is validated by MLR modeling and PCA. Compared
with the results obtained in previous studies, the superiority of
the method is proved. Therefore, the method may be an alternative
tool for classiﬁcation using the expression data.
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